How Long Ipamorelin Stays in Your System: Half-Life

The short version

If you are asking how long does ipamorelin stay in your system, the pharmacology gives a clean answer and the anti-doping labs add a twist. In healthy people, ipamorelin has a terminal half-life of about two hours ^[2] — the time it takes for the blood level to fall by half during clearance. By the standard rule that a drug is mostly gone after five half-lives, the peptide itself is largely cleared within roughly ten hours.

The twist: "cleared from the blood" is not the same as "undetectable." Anti-doping methods find ipamorelin and its breakdown products in urine at picogram concentrations — trillionths of a gram per millilitre ^[7]. So the molecule leaves the bloodstream quickly but can still be caught in a urine test. This page works through both halves of that story.

The two-hour half-life, measured directly

The half-life figure is not an estimate — it was measured in people. A 1999 population pharmacokinetic-pharmacodynamic study gave eight healthy men per dose level five 15-minute intravenous infusions from 4.21 to 140.45 nmol/kg ^[2]. The kinetics were linear and dose-proportional, with a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg ^[2].

Those constants describe a small peptide that distributes into a modest volume and clears at a steady, predictable rate. In rats, plasma clearance is roughly five-fold lower than GHRP-6 — a relative durability that does not change the human picture, where two hours is the operative number.

A single pulse, not a plateau

The effect ipamorelin produces is even shorter-lived than its blood concentration. The growth-hormone response is a single discrete pulse, peaking around 40 minutes (0.67 h) after dosing ^[2] — not a sustained elevation. Growth hormone rises sharply, then falls, mirroring the body's own pulsatile secretion.

That shape matters. A short half-life plus a sharp single pulse is the pharmacological reason research-use protocols favor frequent, timed dosing rather than once-daily administration — though those protocols have no controlled-trial basis. It is also why the compound's window of pharmacological action is brief, even as its detectability in urine outlasts it.

Why detection outlasts the blood level

Here is the part that surprises people. A two-hour half-life suggests a short detection window — and for blood, it is. But urine testing works differently: the kidneys concentrate the parent peptide and its metabolites, and modern instruments are extraordinarily sensitive. A 2012 nano-LC Orbitrap method detected ipamorelin in human urine at 2-10 pg/mL ^[7]; a validated LC-MS method determined it and seven related peptides at 0.2-1 ng/mL ^[9]; and metabolite-mapping work characterized the urinary breakdown products, including after nasal dosing ^[10].

So "how long does it stay in your system" has two answers. In the bloodstream: hours, governed by the ~2-hour half-life ^[2]. In a urine doping test: long enough, and at low enough concentrations, that accredited laboratories reliably catch it ^[7][9]. The metabolite work means even degraded fragments betray its presence ^[10].

What this means for the WADA picture

Ipamorelin is prohibited in sport at all times under WADA category S2, as a growth hormone secretagogue. The combination of a short half-life and validated, sensitive urine detection is exactly why the prohibition is enforceable: athletes cannot rely on rapid blood clearance to evade testing, because the urinary methods are designed around the molecule's metabolites, not just the parent compound ^[7][9][10]. The pharmacokinetics, in other words, are the anti-doping story — which is the lens this whole site reads ipamorelin through.